Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized G-CSF for ventilator-associated pneumonia due to multidrug-resistant Acinetobacter
IRCT20150824023743N2Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Apr 2017
- Modality
- Small Molecules, Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of granulocyte colony-stimulating factor, colistin and meropenem in ventilator-associated pneumonia (VAP) and Acinetobacter infection (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Clinical Pulmonary Infection Score and Achievement in treatment. Started Apr 2017; status: completed.
02
Drugs
granulocyte colony-stimulating factorcolistinmeropenem
03
Conditions
ventilator-associated pneumonia (VAP)Acinetobacter infection
Beyond the preview
Go deeper on IRCT20150824023743N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150824023743N2.